RLAY is expected to report earnings to fall 9.40% to -57 cents per share on February 20
Q4'24
Est.
$-0.57
Q3'24
Beat
by $0.14
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.12
Q4'23
Beat
by $0.05
The last earnings report on November 06 showed earnings per share of -62 cents, beating the estimate of -76 cents. With 1.20M shares outstanding, the current market capitalization sits at 753.22M.
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets